We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AptarGroup (ATR) Hits 52-Week High on Strong Pharma Segment
Read MoreHide Full Article
With enhanced focus on innovative product launches and a robust Pharma segment, AptarGroup, Inc. (ATR - Free Report) scaled a 52-week high of $88.55 on Jul 7, before closing at $88.09.
AptarGroup’s shares climbed 20% year to date, outperforming the Zacks categorized Containers-Paper/Plastic sector's growth of 11.6%. The company has long-term earnings growth rate of 9.33%, making us confident of its innate strength.
AptarGroup has a healthy year-to-date return of 21% and a solid one-year return of 11.7%.
The stock has a market cap of $5.5 billion. Average volume of shares traded over the last three months is approximately 280K. We note that the company has beaten the Zacks Consensus Estimate in three out of the trailing four quarters, the average positive earnings surprise being 1.78%.
For second-quarter 2017, AptarGroup expects earnings to be in the range of 92–97 cents, the mid-point of the guidance reflects 9% year-over-year improvement. Growth will likely be stemmed by the Pharma and Food + Beverage segments. The Pharma segment continues to benefit from solid demand across its portfolio of devices.
During the first quarter, AptarGroup received an order for the first integrated electronic nasal lockout device approved by the EMA, following a multi-year development with Takeda Pharmaceuticals International AG.
Last year, the company entered into a partnership with Propeller Health – a leading digital platform for respiratory health management – to develop a fully integrated connected metered dose inhaler that combines electronic sensing, dose counting and wireless communicating capabilities.
Further, the company has signed an agreement to acquire a 20% minority ownership position in Kali Care, a Silicon Valley-based technology company. AptarGroup’s leading dispensing technologies in combination with Kali Care’s smart sensors, data analytics and cloud services have the prospects to become a valuable solution for clinicians. These strategic collaborations underline the company’s endeavors to bring innovation in healthcare.
Notably, AptarGroup participated in several global beauty product launches, including Estée Lauder's revitalizing eye gel during the quarter. In addition, the company is expanding its presence in the growing color cosmetics market. Its dispensers were selected for two new global liquid foundations by Coty and LVMH.
Zacks Rank & Other Key Picks
At present, AptarGroup carries a Zacks Rank #2 (Buy).
Casella Waste has expected long-term growth of 187.78%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
AptarGroup (ATR) Hits 52-Week High on Strong Pharma Segment
With enhanced focus on innovative product launches and a robust Pharma segment, AptarGroup, Inc. (ATR - Free Report) scaled a 52-week high of $88.55 on Jul 7, before closing at $88.09.
AptarGroup’s shares climbed 20% year to date, outperforming the Zacks categorized Containers-Paper/Plastic sector's growth of 11.6%. The company has long-term earnings growth rate of 9.33%, making us confident of its innate strength.
AptarGroup has a healthy year-to-date return of 21% and a solid one-year return of 11.7%.
The stock has a market cap of $5.5 billion. Average volume of shares traded over the last three months is approximately 280K. We note that the company has beaten the Zacks Consensus Estimate in three out of the trailing four quarters, the average positive earnings surprise being 1.78%.
AptarGroup, Inc. Price and Consensus
AptarGroup, Inc. Price and Consensus | AptarGroup, Inc. Quote
Growth Catalysts
For second-quarter 2017, AptarGroup expects earnings to be in the range of 92–97 cents, the mid-point of the guidance reflects 9% year-over-year improvement. Growth will likely be stemmed by the Pharma and Food + Beverage segments. The Pharma segment continues to benefit from solid demand across its portfolio of devices.
During the first quarter, AptarGroup received an order for the first integrated electronic nasal lockout device approved by the EMA, following a multi-year development with Takeda Pharmaceuticals International AG.
Last year, the company entered into a partnership with Propeller Health – a leading digital platform for respiratory health management – to develop a fully integrated connected metered dose inhaler that combines electronic sensing, dose counting and wireless communicating capabilities.
Further, the company has signed an agreement to acquire a 20% minority ownership position in Kali Care, a Silicon Valley-based technology company. AptarGroup’s leading dispensing technologies in combination with Kali Care’s smart sensors, data analytics and cloud services have the prospects to become a valuable solution for clinicians. These strategic collaborations underline the company’s endeavors to bring innovation in healthcare.
Notably, AptarGroup participated in several global beauty product launches, including Estée Lauder's revitalizing eye gel during the quarter. In addition, the company is expanding its presence in the growing color cosmetics market. Its dispensers were selected for two new global liquid foundations by Coty and LVMH.
Zacks Rank & Other Key Picks
At present, AptarGroup carries a Zacks Rank #2 (Buy).
Other top-ranked companies in the industrial products space include Apogee Enterprises, Inc. (APOG - Free Report) , Deere & Company (DE - Free Report) and Casella Waste Systems, Inc. (CWST - Free Report) , each boasting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Apogee has expected long-term growth of 3.42%.
Deere has expected long-term growth of 70.41%.
Casella Waste has expected long-term growth of 187.78%.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>